NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine... ( ROCKVILLE Md. Dec. 9 /- Novavax Inc.(...)

HOME >> BIOLOGY >> TECHNOLOGY

NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate

Date:12/9/2008

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and the University of Massachusetts Medical School announced results from a preclinical study of a Respiratory Syncytial Virus ("RSV") vaccine candidate. Novavax has licensed exclusive worldwide rights from the University of Massachusetts Medical School to certain technology for the development and commercialization of Paramyxovirus vaccines incorporating certain Virus-Like-Particles ("VLPs"). This vaccine candidate is Novavax's first recombinant VLP for the prevention of RSV disease.

The preclinical study evaluated the immunogenicity and efficacy of the RSV VLP vaccine candidate in mice. The VLP contains the matrix (i.e., "core") protein of Newcastle Disease Virus decorated with a human RSV attachment glycoprotein (Ga), which is important for inducing immunity against RSV. In this study, mice were immunized with one of four doses of the RSV VLP vaccine candidate, inactivated RSV, live RSV, or a placebo. The antibody responses to the RSV VLPs were robust and higher than the antibody responses to inactivated or live RSV. Further, antibody titers increased with higher VLP doses.

Subsets of mice that had been immunized with either RSV VLPs via intraperitoneal inoculation or live RSV via intranasal inoculation received a vaccine booster dose and were challenged with live RSV intra-nasally. Unimmunized mice were evaluated as controls. The VLP-immunized mice were protected from RSV replication in the lungs. Further, the lung tissue of these mice showed no evidence of enhanced inflammation after RSV challenge/infection, which has been reported with a formalin-inactivated RSV vaccine.

In summary, the candidate VLP vaccine induced strong antibody responses against RSV, protected mice against RSV replication i
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
3. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
4. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
5. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
6. Novavax CEO to Present at BIO Investor Forum 2008
7. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
8. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
9. Novavax Announces Closing of $18 Million Registered Direct Offering
10. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
11. Novavax to Join Russell 3000 Index

Post Your Comments:

NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine...( ROCKVILLE Md. Dec. 9 /- Novavax Inc.(...)